Probing the importance of second sphere residues in an esterolytic antibody by phage display

Journal of Molecular Biology

Volumn 284, Issue 4, 1998, Pages 1083-1094

  Arkin, Michelle R ^a,b   Wells, James A ^a,b  

^a GENENTECH INC   (United States)

^b Sunesis Pharmaceuticals Inc   (United States)

Author keywords

Abzyme; Catalytic antibody; In vitro evolution; Site directed mutagenesis; Transition state analog

Indexed keywords

CATALYTIC ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN HEAVY CHAIN; MUTANT PROTEIN;

ANTIBODY COMBINING SITE; ANTIBODY STRUCTURE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BINDING KINETICS; CONTROLLED STUDY; CRYSTAL STRUCTURE; PHAGE DISPLAY; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS;

FELIS CATUS;

EID: 0032509131     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.1998.2234     Document Type: Article

References (44)

1. Angeles T. S., Smith R. G., Darsley M. J., Sugasawara R., Sanchez R. I., Kenten J., Schultz P. G., Martin M. T. Isoabzymes: structurally and mechanistically similar catalytic antibodies for the same immunization. Biochemistry. 32:1993;12128-12135.
2. Baca M., Scanlan T. S., Stephenson R. C., Wells J. A. Phage display of a catalytic antibody to optimize affinity for transition-state analog binding. Proc. Natl Acad. Sci. USA. 94:1997;10063-10068.
3. Benkovic S. J. Catalytic antibodies. Annu. Rev. Biochem. 61:1992;29-54.
4. Castro B., Evin G., Selve C., Seyer R. Peptide coupling reagents; VIII. A high yield preparation of phenyl esters of amino acids using benzotriazolyloxytris[dimethylamino]phosphonium hexafluorophosphate (BOP reagent). Synthesis. 413:1977.
5. Charbonnier J.-B., Golinelli-Pimpaneau B., Gigant B., Tawfik D. S., Chap R., Schindler D. G., Kim S.-H., Green B. S., Eshhar Z., Knossow M. Structural convergence in the active sites of a family of catalytic antibodies. Science. 275:1997;1140-1142.
6. Cunningham B. C., Lowe D. G., Li B., Bennett B. D., Wells J. A. Production of an atrial natriuretic peptide variant that is specific for type A receptor. EMBO J. 13:1994;2508-2515.
7. Fersht A. R. Relationships between apparent binding energies measured in site-directed mutagenesis experiments and energetics of binding and catalysis. Biochemistry. 27:1988;1577-1580.
8. Fujii I., Tanaka F., Miyashita H., Tanimura R., Kinoshita K. Correlation between antigen-combining-site structures and functions within a panel of catalytic antibodies generated against a single transition state analog. J. Am. Chem. Soc. 117:1995;6199-6209.
9. Gao C., Lavey B. J., Lo C.-H. L., Datta A., Wentworth P. Jr, Janda K. D. Direct selection for catalysis from combinatorial antibody libraries using a boronic acid probe: primary amide bond hydrolysis. J. Am. Chem. Soc. 120:1998;2211-2217.
10. Gao Q. S., Sun M., Rees A. R., Paul S. Site-directed mutagenesis of proteolytic antibody light chain. J. Mol. Biol. 253:1995;658-664.
11. Gigant B., Charbonnier J.-B., Eshhar Z., Green B. S., Knossow M. X-ray structures of a hydrolytic antibody and of complexes elucidate catalytic pathway from substrate binding and transition state stabilization through water attack and product release. Proc. Natl Acad. Sci. USA. 94:1997;7857-7861.
12. Guo J., Huang W., Scanlan T. S. Kinetic and mechanistic characterization of an efficient hydrolytic antibody: evidence for the formation of an acyl intermediate. J. Am. Chem. Soc. 116:1994;6062-6069.
13. Guo J., Huang W., Zhou G. W., Fletterick R. J., Scanlan T. S. Mechanistically different catalytic antibodies obtained from immunization with a single transition-state analog. Proc. Natl Acad. Sci. USA. 92:1995;1694-1698.
14. Jackson D. Y., Prudent J. R., Baldwin E. P., Schultz P. G. A mutagenesis study of a catalytic antibody. Proc. Natl Acad. Sci. USA. 88:1991;58-62.
15. Janda K. D., Lo L.-C., Lo C.-H. L., Sim M.-M., Wang R., Wong C.-H., Lerner R. A. Chemical selection for catalysis in combinatorial antibody libraries. Science. 275:1997;945-948.
16. Jencks W. P. Catalysis in Chemistry and Enzymology. 1969;McGraw-Hill, New York.
17. Kabat E. A., Wu T. T., Perry H. M., Gottesman K. S., Foeller C. Sequences of Proteins of Immunological Interest. 1991;Public Health Service, National Institutes of Health, Bethesda.
18. Kunkel T. A., Bebenek K., McClary J. Efficient site-directed mutagenesis using uracil-containing DNA. Methods Enzymol. 204:1991;125-139.
19. Lesley S. A., Patten P. A., Schultz P. G. A genetic approach to the generation of antibodies with enhanced catalytic activities. Proc. Natl Acad. Sci. USA. 90:1993;1160-1165.
20. Lowman H. B., Bass S. H., Simpson N., Wells J. A. Selecting high-affinity binding proteins by monovalent phage display. Biochemistry. 30:1991;10832-10838.
21. MacBeath G., Hilvert D. Hydrolytic antibodies: variations on a theme. Chem. Biol. 3:1996;433-445.
22. Mader M. M., Bartlett P. A. Binding energy and catalysis: the implications for transition-state analogs and catalytic antibodies. Chem. Rev. 97:1997;1281-1301.
23. Miyashita H., Hara T., Tanimura R., Fukuyama S., Cagnon C., Kohara A., Fujii I. Site-directed mutagenesis of active site contact residues in a hydrolytic abzyme: evidence for an essential histidine involved in transition state stabilization. J. Mol. Biol. 267:1997;1247-1257.
24. Parmley S. F., Smith G. P. Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. Gene. 73:1988;305-318.
25. Patten P. A., Gray N. S., Yang P. L., Marks C. B., Wedemayer G. J., Boniface J. J., Stevens R. C., Schultz P. G. The immunological evolution of catalysis. Science. 271:1996;1086-1091.
26. Pauling L. Nature of forces between large molecules of biological interest. Nature. 161:1948;707-709.
27. Phillips M. A., Kaplan A. P., Rutter W. J., Bartlett P. A. Transition-state characterization: a new approach combining inhibitor analogues and variation in enzyme structure. Biochemistry. 31:1992;959-963.
28. Pollack S. J., Jacobs J. W., Schultz P. G. Selective chemical catalysis by an antibody. Science. 234:1986;1570-1573.
29. Schier R., McCall A., Adams G. P., Marshall K. W., Merritt H., Yim M., Crawford R. S., Weiner L. M., Marks C., Marks J. D. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J. Mol. Biol. 263:1996;551-567.
30. Schrader T. Strong binding of alkylguanidinium ions by molecular tweezers - an artificial selective arginine receptor molecule with a biomimetic recognition pattern. Chemistry-A Europ. J. 3:1997;1537-1541.
31. Schultz P. G., Lerner R. A. From molecular diversity to catalysis: lessons from the immune system. Science. 269:1995;1835-1842.
32. Smiley J. A., Benkovic S. J. Selection of catalytic antibodies for a biosynthetic reaction from a combinatorial cDNA library by complementation of an auxotrophic E. coli: antibodies for orotate decarboxylation. Proc. Natl Acad. Sci. USA. 91:1994;8319-8323.
33. Stewart J. D., Benkovic S. J. Transition-state stabilization as a measure of the efficiency of antibody catalysis. Nature. 375:1995;388-391.
34. Stewart J. D., Roberts V. A., Thomas N. R., Getzoff E. D., Benkovic S. J. site-directd mutagenesis of a catalytic antibody: an arginine and a histidine residue play key roles. Biochemistry. 33:1994;1994-2003.
35. Tomlinson I. M., Walter G., Jones P. T., Dear P. H., Sonnhammer E. L. L., Winter G. the imprint of somatic hypermutation on the repertoire of human germline V genes. J. Mol. Biol. 256:1996;813-817.
36. Tramontano A., Janda K. D., Lerner R. A. Catalytic antibodies. Science. 234:1986;1566-1570.
37. Ulrich H. D., Mundorff E., Santarsiero B. D., Driggers E. M., Stevens R. C., Schultz P. G. The interplay between binding energy and catalysis in the evolution of a catalytic antibody. Science. 389:1997;271-275.
38. Wade H., Scanlan T. S. P1-S1 interactions control the enantioselectivity and hydrolytic activity of the norleucine phenylesterase catalytic antibody 17E8. J. Am. Chem. Soc. 118:1996;6510-6511.
39. Wedemayer G. J., Patten P. A., Wang L. H., Schultz P. G., Stevens R. C. Structural insight into the evolution of an antibody combining site. Science. 276:1997;1665-1669.
40. Wells J. A. Additivity of mutational effects in proteins. Biochemistry. 29:1990;8509-8517.
41. Yang G., Chun J., Arakawa-Uramoto H., Wang X., Gawinowicz M. A., Zhao K., Landry D. W. Anti-cocaine catalytic antibodies: a synthetic approach to improved antibody diversity. J. Am. Chem. Soc. 118:1996;5881-5890.
42. Yang W.-P., Green K., Pinz-Sweeney S., Briones A. T., Burton D. R., Barbas C. F. III. CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J. Mol. Biol. 254:1995;392-403.
43. Zemel R., Schindler D. G., Tawfik D. S., Eshhar Z., Green B. S. Differences in the biochemical properties of esterolytic antibodies correlate with the structural diversity. Mol. Immunol. 31:1994;127-137.
44. Zhou G. W., Guo J., Huang W., Fletterick R. J., Scanlan T. S. Crystal structure of a catalytic antibody with a serine protease active site. Science. 265:1994;1059-1064.